Comprehensive medication guide to Otezla including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$150 copay with commercial insurance and Amgen copay assistance; Otezla is placed on specialty Tier 4–5 on most formularies. Prior authorization required by nearly all plans. Medicare patients subject to Part D cost-sharing, capped at $2,000/year OOP under the IRA (2025).
Estimated Cash Pricing
$5,000–$6,800 retail per month for Otezla brand; no US generic is available until approximately 2028–2029. With Amgen's commercial copay card, eligible insured patients may pay as little as $0 per fill.
Medfinder Findability Score
65/100
Summarize with AI
On this page
Otezla (apremilast) is an oral prescription medication manufactured by Amgen Inc. It is classified as a phosphodiesterase 4 (PDE4) inhibitor — a type of small-molecule drug that works inside immune cells to reduce inflammation. Otezla was first approved by the FDA in March 2014 and has since been used by over 650,000 patients worldwide.
Otezla is FDA-approved for three conditions: plaque psoriasis (in adults and children ages 6+ weighing at least 20 kg), active psoriatic arthritis (in adults and children ages 6+ weighing at least 20 kg), and oral ulcers associated with Behçet's disease (in adults, approved 2019). In 2021, the FDA expanded Otezla's approval to cover adults with plaque psoriasis across all severity levels, making it the first oral treatment approved for mild, moderate, and severe plaque psoriasis.
Otezla is available as immediate-release tablets (10 mg, 20 mg, 30 mg) and as the extended-release formulation Otezla XR (75 mg). The maintenance dose for adults is 30 mg twice daily (Otezla) or 75 mg once daily (Otezla XR). Treatment always begins with a 5-day titration schedule to minimize gastrointestinal side effects during initiation.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Otezla works by selectively inhibiting the enzyme phosphodiesterase 4 (PDE4) inside immune cells. PDE4's normal function is to break down a molecule called cyclic AMP (cAMP) into an inactive form. cAMP acts as a natural brake on inflammatory signaling — when PDE4 destroys it, the brakes come off and inflammation can intensify. By blocking PDE4, Otezla allows cAMP levels to remain elevated inside immune cells.
Elevated cAMP then triggers a downstream reduction in pro-inflammatory molecules — including TNF-alpha, IL-17, and IL-23 — while simultaneously increasing the production of anti-inflammatory IL-10. The result is a broad dampening of the inflammatory cycle that drives psoriatic disease and related conditions.
Unlike biologics (which target specific inflammatory proteins outside cells via injection), Otezla is an oral small molecule that works intracellularly. It has approximately 73% oral bioavailability, reaches peak blood levels about 2.5 hours after dosing, and has an elimination half-life of 6–9 hours. It is metabolized primarily via the liver's CYP3A4 enzyme pathway.
10 mg — tablet
Titration dose (Days 1-5 initiation pack)
20 mg — tablet
Titration dose (Days 3-5 initiation pack)
30 mg — tablet
Maintenance dose — 30 mg twice daily (morning and evening)
75 mg — extended-release tablet
Otezla XR — once daily maintenance dose; equivalent to 30 mg BID
Otezla is not on the FDA Drug Shortage Database in 2026 — Amgen's supply chain is stable and the drug is manufactured consistently. However, access is genuinely difficult for many patients due to structural barriers: Otezla is only dispensed through specialty pharmacies (not standard retail pharmacies), virtually all insurance plans require prior authorization (typically taking 1–4 weeks), most plans apply step therapy requirements, and the list price of $5,000–$6,800/month is prohibitive without financial assistance.
The specialty pharmacy requirement means patients cannot simply walk into a local CVS or Walgreens to pick up Otezla — it must be dispensed through designated specialty pharmacies like CVS Specialty, Walgreens Specialty, Accredo, or Optum Rx Specialty. Enrollment in Amgen SupportPlus (1-833-442-6436) is the recommended first step, as it routes your prescription, coordinates insurance, and connects you with financial assistance in one program.
If you need help locating a pharmacy that can fill your Otezla prescription, medfinder contacts pharmacies on your behalf and texts you the results — saving you the time and frustration of navigating the specialty pharmacy landscape on your own.
Otezla (apremilast) is not a controlled substance and has no DEA prescribing restrictions. Any licensed prescriber with a valid DEA number and medical license can write for Otezla. However, because the drug is indicated for specific inflammatory conditions and insurance prior authorization typically requires documentation from a relevant specialist, the vast majority of initial prescriptions come from dermatologists and rheumatologists.
Dermatologists: Primary prescribers for plaque psoriasis across all severity levels
Rheumatologists: Primary prescribers for psoriatic arthritis
Primary Care Physicians (PCPs): May prescribe for ongoing management of established patients
Nurse Practitioners (NPs) and Physician Assistants (PAs): Can prescribe in states where they have full prescriptive authority, often within dermatology or rheumatology practices
Internists and immunologists: May prescribe for Behçet's disease or complex inflammatory presentations
Telehealth platforms offering board-certified dermatology consultations can also prescribe Otezla in many states for plaque psoriasis. Platforms such as Teladoc, MDLive, Hims & Hers, and dedicated teledermatology services offer video visit options that may be faster than waiting for an in-person specialist appointment, which can have wait times of 2–8+ weeks in many areas.
No. Otezla (apremilast) is not a controlled substance and has no DEA scheduling. It does not have abuse potential or dependency risk. Any licensed prescriber can write a prescription for Otezla without any special DEA registration or controlled substance prescribing authority.
Because Otezla is not a controlled substance, prescriptions can be issued electronically (e-prescribed), called in, or faxed to specialty pharmacies. There are no restrictions on the number of refills, and patients can receive 90-day supplies when available through their specialty pharmacy. The prescription process is the same as for any non-controlled specialty medication.
The most common side effects of Otezla (occurring in ≥5% of patients with plaque psoriasis) include:
Diarrhea (approximately 25% of patients)
Nausea
Upper respiratory tract infection
Headache (including tension headache)
Vomiting
Upper abdominal pain
Nasopharyngitis
Back pain
Serious side effects to monitor:
Depression, suicidal ideation, or mood changes — contact doctor immediately if these develop
Significant weight loss (5–10% in ~10% of patients vs. 3.3% on placebo) — monitor weight regularly
Severe GI complications including dehydration from persistent diarrhea/vomiting — may require hospitalization in severe cases
Hypersensitivity reactions including angioedema and anaphylaxis (rare; post-marketing)
Know what you need? Skip the search.
Methotrexate
Affordable oral DMARD for psoriasis and psoriatic arthritis; requires regular lab monitoring; generic available under $30/month
Deucravacitinib (Sotyktu)
Newer oral TYK2 inhibitor approved 2022 for moderate-to-severe plaque psoriasis; once daily; may offer better skin clearance than Otezla
Adalimumab (Humira) and biosimilars
Injectable TNF inhibitor biologic; multiple biosimilars now available at lower cost; approved for psoriasis and psoriatic arthritis
Secukinumab (Cosentyx)
Injectable IL-17A inhibitor biologic; high skin clearance rates; approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis
Prefer Otezla? We can find it.
Rifampin
majorStrong CYP450 inducer; reduces Otezla AUC by 72% and Cmax by 43%; co-administration not recommended due to likely loss of efficacy
Carbamazepine (Tegretol)
majorStrong CYP450 inducer; significantly reduces apremilast blood levels; co-administration not recommended
Phenobarbital
majorStrong CYP450 inducer; reduces apremilast exposure; co-administration not recommended
Phenytoin (Dilantin)
majorStrong CYP450 inducer; reduces apremilast exposure; co-administration not recommended
St. John's Wort
majorHerbal supplement and strong CYP450 inducer; may significantly reduce apremilast levels; co-administration not recommended
Apalutamide (Erleada)
majorStrong CYP3A4 inducer used in prostate cancer; avoid or use alternate drug with apremilast
Methotrexate
minorNo clinically significant pharmacokinetic interaction; can be used concomitantly with Otezla
Oral contraceptives
minorNo significant interaction with ethinyl estradiol/norgestimate; Otezla does not affect contraceptive efficacy
Otezla occupies a unique position in the treatment landscape for psoriatic disease: it offers oral convenience, broad inflammatory modulation, and no requirement for blood monitoring — making it a practical option for patients who prefer to avoid injections or have relative contraindications to biologics. It is the only oral treatment approved for plaque psoriasis across all severity levels, and it has a decade of real-world safety experience behind it with over 650,000 patients treated globally.
The practical challenge with Otezla in 2026 is access, not supply. The combination of specialty pharmacy exclusivity, universal prior authorization requirements, step therapy mandates, and a high list price creates a complex access landscape that can delay treatment for weeks or months. Amgen's support programs — particularly the commercial copay card and Bridge to Commercial Coverage program — significantly reduce the cost burden for most commercially insured patients. Medicare beneficiaries now benefit from the $2,000 annual OOP cap under the Inflation Reduction Act.
If you're struggling to locate a pharmacy that can fill your Otezla prescription, medfinder contacts pharmacies on your behalf and texts you the results — helping you cut through the complexity and get the medication you need.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini